Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on December 21, 2018. The filing primarily announces the entry into a material definitive agreement to refinance the Company's existing secured term loan facility and provides updates on regulatory matters and clinical trial progress.
Key Financial Metrics and Debt Structure
The Company entered into a Third Amended and Restated Credit and Security Agreement with MidCap Financial Trust, Silicon Valley Bank, and Flexpoint MCLS SPV LLC. Key terms include:
- Facility Size: Increased from $18.0 million to $25.0 million, with the full amount drawn at closing.
- Use of Proceeds: Approximately $12.3 million used to pay off the prior outstanding principal balance; remaining funds available for operations.
- Interest Rate: LIBOR-based rate with a 2.00% floor, plus 7.25%.
- Term: Extended to December 21, 2023.
- Repayment Terms: Interest-only payments permitted until January 1, 2021. This period may be extended to January 1, 2022, if DEXTENZA net sales exceed $40.0 million in a trailing twelve-month period prior to December 1, 2020.
- Fees: 0.5% loan origination fee; prepayment fees ranging from 4.0% to 1.0% depending on timing; 3.5% final payment fee upon maturity.
- Covenants: Requires maintaining at least $5.0 million in cash and/or cash equivalents at all times.
The filing does not provide specific revenue, profit, or cash flow figures for the reporting period, as this is a current report regarding specific events rather than a periodic financial statement.
Material Changes and Operational Updates
Debt Refinancing: The Company successfully refinanced its debt, increasing the principal amount and extending the maturity date, which improves liquidity and extends the cash runway.
Regulatory Update (ReSure Sealant): The FDA rejected the Company's appeal of a warning letter received in October 2018 regarding a post-approval trial for ReSure Sealant. Failure to conduct the trial to the FDA's satisfaction may result in withdrawal of approval. The product remains commercially available but without sales support, with limited revenue anticipated for 2019.
Clinical Update (OTX-TKI): The Company is screening patients for a Phase 1 clinical trial outside the U.S. and now expects to dose the first patient in the first quarter of 2019.
Guidance, Outlook, and Risks
Cash Runway: Based on current plans and the proceeds from the refinancing, the Company believes it can fund operating expenses, debt service, and capital expenditures into the third quarter of 2019. This estimate excludes potential payments from a collaboration with Regeneron Pharmaceuticals and does not reflect the full costs of building a sales force for DEXTENZA.
Capital Needs: The Company explicitly states it will need to raise additional capital to support the potential building of a sales force for DEXTENZA.
Risks: Key risks include the potential withdrawal of FDA approval for ReSure Sealant, the sufficiency of cash resources, and the ability to meet financial covenants. The Company notes that actual results may differ materially from forward-looking statements due to various uncertainties.
Investor Verification Checklist
- Verify the Company's ability to maintain the $5.0 million cash covenant under the new credit agreement.
- Monitor the status of the ReSure Sealant post-approval trial and any further FDA communications regarding the warning letter.
- Assess the timeline and capital requirements for the planned DEXTENZA sales force build-out.
- Track the progress of the OTX-TKI Phase 1 trial and the timing of the first patient dose.
- Review the Company's cash burn rate to confirm the runway extends into the third quarter of 2019 as projected.